Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial

Deborah Cromer, Arnold Reynaldi, Megan Steain, James A Triccas, Miles P Davenport, David S Khoury
doi: https://doi.org/10.1101/2021.06.29.21259504

Article usage

Article usage: July 2021 to January 2025

AbstractFullPdf
Jul 20211101180350
Aug 2021470138250
Sep 2021848245353
Oct 20212971560
Nov 2021203448
Dec 2021188217
Jan 2022210615
Feb 2022122316
Mar 2022125318
Apr 2022107014
May 2022103319
Jun 202213818
Jul 202211056
Aug 20227017
Sep 202291111
Oct 202212016
Nov 202210226
Dec 20226634
Jan 202362115
Feb 20235945
Mar 20237045
Apr 20235224
May 20235627
Jun 20235442
Jul 20235713
Aug 202353125
Sep 20235656
Oct 20236104
Nov 202344111
Dec 20233805
Jan 20243504
Feb 20243735
Mar 20244202
Apr 202467310
May 20243714
Jun 20245014
Jul 20245348
Aug 20244528
Sep 202464310
Oct 20244527
Nov 20243905
Dec 20243519
Jan 2025711
Back to top
Posted June 30, 2021.
Download PDF
Data/Code
Email
Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial
Deborah Cromer, Arnold Reynaldi, Megan Steain, James A Triccas, Miles P Davenport, David S Khoury
medRxiv 2021.06.29.21259504; doi: https://doi.org/10.1101/2021.06.29.21259504
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area